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The prevalence of heart failure increases in the aging population and following myocardial
infarction (MI), yet the extracellular matrix (ECM) remodeling underpinning the development
of aging- and MI-associated cardiac fibrosis remains poorly understood. A link between
inflammation and fibrosis in the heart has long been appreciated, but has mechanistically
remained undefined. We investigated the expression of a novel protein, extracellular matrix
protein 1 (ECM1) in the aging and infarcted heart.
Methods
Young adult (3-month old) and aging (18-month old) C57BL/6 mice were assessed. Young
mice were subjected to left anterior descending artery-ligation to induce MI, or transverse
aortic constriction (TAC) surgery to induce pressure-overload cardiomyopathy. Left ventricle
(LV) tissue was collected early and late post-MI/TAC. Bone marrow cells (BMCs) were iso-
lated from young healthy mice, and subject to flow cytometry. Human cardiac fibroblast
(CFb), myocyte, and coronary artery endothelial & smooth muscle cell lines were cultured;
human CFbs were treated with recombinant ECM1. Primary mouse CFbs were cultured and
treated with recombinant angiotensin-II or TGF-β1. Immunoblotting, qPCR and mRNA fluo-
rescent in-situ hybridization (mRNA-FISH) were conducted on LV tissue and cells.
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Results
ECM1 expression was upregulated in the aging LV, and in the infarct zone of the LV early
post-MI. No significant differences in ECM1 expression were found late post-MI or at any
time-point post-TAC. ECM1 was not expressed in any resident cardiac cells, but ECM1 was
highly expressed in BMCs, with high ECM1 expression in granulocytes. Flow cytometry of
bone marrow revealed ECM1 expression in large granular leucocytes. mRNA-FISH
revealed that ECM1 was indeed expressed by inflammatory cells in the infarct zone at day-3
post-MI. ECM1 stimulation of CFbs induced ERK1/2 and AKT activation and collagen-I
expression, suggesting a pro-fibrotic role.
Conclusions
ECM1 expression is increased in ageing and infarcted hearts but is not expressed by resi-
dent cardiac cells. Instead it is expressed by bone marrow-derived granulocytes. ECM1 is
sufficient to induce cardiac fibroblast stimulation in vitro. Our findings suggest ECM1 is
released from infiltrating inflammatory cells, which leads to cardiac fibroblast stimulation
and fibrosis in aging and MI. ECM1 may be a novel intermediary between inflammation and
fibrosis.
Introduction
Heart failure (HF) causes significant morbidity and mortality, and aging is the strongest risk
factor for HF due to its association with inflammation and progressive fibrosis [1–4]. Cardiac
fibrosis is the result of the net accumulation of extracellular matrix (ECM) proteins during tis-
sue remodelling, which causes myocardial stiffness and significantly impairs cardiac structure
and function, and leads to HF [3, 5–12]. Fibrosis is a hallmark of the aging and infarcted heart,
however the mechanisms underpinning the development of fibrosis are disease-specific [13].
Two of the most common cardiac heart failure models are pressure-overload induced cardio-
myopathy and myocardial infarction (MI) [14–16]. Pressure-overload cardiomyopathy
induces fibrosis as the result of large scale hemodynamic stress and left ventricle (LV) hyper-
trophy [17]. MI is associated with intense early inflammation, followed by ECM remodeling of
the infarct zone and adjacent tissue, leading to collagen accumulation and fibrosis. This alters
cardiac structure and function with an increased likelihood of heart failure [12, 18, 19]. The
aggressive inflammation that occurs post-MI is well documented and referred to as the
‘inflammatory phase’ (~0–3 days post-MI). This is followed by a ‘proliferative phase’ (~2–7
days post-MI) which consists of fibrotic tissue deposition and angiogenesis, and a ‘maturation
phase’ (~7+ days post-MI) which consists of ECM crosslinking and vascular maturation [20,
21].
Currently, the molecular events underpinning ECM remodeling are incompletely under-
stood. As a result, there are few effective treatments for cardiac fibrosis. Extracellular matrix
protein 1 (ECM1) is a widely expressed 85-kDa glycoprotein protein encoded by the ECM1
gene located at chromosome 1q21 in humans [22]. ECM1 is a multifunctional protein that
interacts with the majority of other ECM proteins. Through these interactions, ECM1
enhances ECM protein binding and mediates a variety of processes in many tissues. The pro-
cesses involved include the regulation of dermal-epidermal ECM integrity and barrier function
[23–25], regulation of T helper lymphocyte type 2 (TH2) cell migration [26], inflammatory
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bowel disease [27], endochondral bone formation [28], stimulation of angiogenesis and
tumour progression [29–32], and mediation of Trastuzumab resistance in breast cancer [33].
The cell types that express ECM1 are unknown, although it was initially identified to be
expressed by the murine osteogenic stromal cell line MN7 [22], and later TH1 and TH2 lym-
phocytes [26]. Despite the abundant evidence highlighting its crucial role in other tissues, the
role of ECM1 in cardiovascular disease is currently unknown.
Therefore, we studied ECM1 expression in aging and diseased hearts and explored the
mechanisms of its actions in order to more clearly understand ECM remodeling and identify
novel therapeutic targets to develop effective medical treatments for cardiac fibrosis.
Materials & methods
Mouse studies and ethics
Male C57Bl/6 mice were used for all experiments, with the exception of bone marrow cell
(BMC) experiments where both male and female mice were used; young mice were 2–3
months old, aging mice were 18 months old. Mice were used with approval from the Univer-
sity of Newcastle’s animal care and ethics committee (ACEC, approval numbers A-2014-409 &
A-2014-435), and according to the NIH guidelines and the guidelines of the Institutional Ani-
mal Care and Use Committee of UCSF the University of California. All experimental proce-
dures conducted on mice were in strict accordance with the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes. Animals were anesthetized with 5% iso-
flurane, and sacrificed vie 5% isoflurane anesthesia followed by exsanguination. All efforts
were made to minimise animal suffering.
Human studies and ethics
All patients provided written informed consent for tissue collection for experimental purposes,
and all protocols were conducted in strict accordance with the Australian National Statement
on Ethical Conduct in Human Research 2007, and approved by the University of Newcastle’s
Human Research Ethics Committee (HREC); approval number H-2014-0390. Written consent
was obtained, and right atrial appendage tissue was collected from ischemic heart disease
patients undergoing coronary artery bypass grafting procedure.
Inducing MI and pressure-overload in mice
MI was surgically induced by performing left anterior descending (LAD) ligation surgery [34],
and pressure-overload by transverse aortic constriction (TAC) [17], as we have previously
described in young mice. Briefly, mice were anesthetized, intubated and placed supine on a
heat mat to maintain their temperature at 37˚C. For induction of MI, a thoracotomy was per-
formed, and the LAD ligated using a 7–0 prolene suture. For induction of pressure-overload
cardiomyopathy, a 6–0 polypropylene suture was tied around a 27G needle placed over the
aortic arch, and the needle was removed. For both LAD-ligation and TAC, the chest was then
closed, and the animal allowed to recover to day-3 or day-28 post LAD-ligation and day-3 or
week-13 post-TAC.
Tissue preparation and analysis
Mice were humanely euthanized as previously described [35] and whole hearts were surgically
removed and perfused with 0.5 mL saline through the aorta, and the LV was snap frozen and
stored at -80˚C. MI tissue was separated into three distinct zones prior to snap freezing
depending on distance from the site of infarct: infarct zone, border zone, and remote zone. For
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TAC studies, the whole LV was used. mRNA and protein extraction and quantification meth-
ods are specified in S1 Text. Briefly, protein and mRNA was extracted, and subject to western
blotting and quantitative polymerase chain reaction (qPCR) analysis respectively to analyze
ECM1 expression, as we have previously described [36]; qPCR primer sequences listed in the
S1 Table. All ECM1 mRNA expression data is expressed as fold-change in delta delta threshold
cycle (ΔΔCt) relative to control ECM1 mRNA expression, and normalized to Tpt-1 housekeep-
ing gene. All western blot ECM1 protein expression data was normalized to either β-tubulin
(55kDa) or β-actin (42kDa) as the loading control for relative band density analysis. An addi-
tional cohort of young healthy control mice were used for cardiac fibroblast (CFb) cell culture
experiments. Protein was extracted from primary mouse and human CFbs and the following
commercially sourced human cardiac cell lines: CFbs (Sigma Aldrich), coronary artery endo-
thelial and smooth muscle cells (HCAEC & HCAESMC respectively; Sigma Aldrich), and
human cardiac myocytes (HCM; PromoCell); n = 1 technical replicates/cell line. BMCs for the
below mRNA fluorescent in-situ hybridization (mRNA-FISH) protocol were extracted as
described by Liu and Quan [37]. BMCs were analyzed whole (n = 3), or separated in mononu-
clear and granulocyte cell fractions (n = 4) with Ficoll-Paque PREMIUM 1.084 (GE Health-
care) as per the manufacturer protocol. Frozen tissue sections (day-3 post-MI) to be used in
mRNA-FISH were sectioned at 8μm using a Leica CM1950 cryostat at -20˚C, as per the manu-
facturer protocol.
Cell culture
Specific primary mouse and human CFb cell culture methods are outlined in S1 Text. Briefly,
mouse primary CFbs were serum starved for 24 h, followed by treatment with either recombi-
nant angiotensin-II (Ang-II; 100nM), transforming growth factor β1 (TGF-β1; 10ng/ml) or
Complete CFb Media alone, for 48 h. Primary human CFb cells were cultured under standard
conditions. Cell culture of commercially sourced human CFb, HCM, HCAEC and HCASMC
cell lines were performed with recommended reagents as per the manufacturer’s protocols.
Human CFbs (Sigma Aldrich) were serum starved for 24 h, then treated with recombinant
ECM1 (20ng/ml) for 10, 30 or 50min to investigate ERK1/2, AKT and p38 pathway activation,
or 48 hours to investigate collagen-I expression. Protein and mRNA were extracted from cells
for use in SDS-PAGE, Western Blot and qPCR.
mRNA-FISH
Oligonucleotide mRNA FISH probes were sourced from LGC Biosearch Technologies (Stel-
laris) for both ‘Ship Ready’ Mouse GAPDH, and custom Stellaris made Mouse ECM1; ECM1
and GAPDH probe sets were conjugated with Quasar 670 dye. mRNA-FISH was conducted
on fresh extracted BMCs, and cryostat-sectioned 8 μm frozen tissue sections as per the Stellaris
‘Cells in Suspension’ and ‘Frozen Tissue’ RNA FISH protocols. Cells and tissue were imaged
using fluorescence microscopy (Zeis; Axio Imager M2) under DAPI and Cy5 channels to
detect nuclear stain 4’,6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) and Quasar 670
dye, respectively.
Flow cytometry
Bone marrow cells were collected from 4 mice. Cells were blocked with Fc block (anti-CD16/
32) for 30 min and stained with the antibodies depicted in Table 1. Staining and washing steps
were performed with FBS stain buffer (554656, BD Biosciences). Samples were acquired on a
BD LSR Fortessa X-20 flow cytometer.
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Flow cytometry data were analysed using FlowJo (version 10). Cells were gated using
FSC-A vs SSC-A, and single-cells identified using FSC-A vs FSC-H. Of these populations,
50,000 cells from each animal were downsampled and concatenated to one .fcs file. t-distrib-
uted stochastic neighbour embedding (tSNE) analysis was performed on the concatenated
sample containing the gated populations from all four samples combined. For this, all compen-
sated channels were assessed (FITC, PerCP-Cy5.5, BV421, BV510, BV650, BV711, BV786, PE,
PE-CF594, PE-Cy7, APC) under the following tSNE settings: Iteration 1000, Perplexity 20, Eta
200, Theta 0.5. Histograms established from the same plot show the differential expression of
the cell markers in ECM1+ and ECM1- cells.
Statistical analysis
Data are represented as mean ± standard deviation. Parametric data were analyzed using t-
tests for two groups, or one-way ANOVA for more than two groups. Multiple comparisons
were assessed for normalcy of distribution (parametric distribution) using Shapiro-Wilk
tests. Non-parametric data were analyzed using Mann-Whitney tests, or Kruskal-Wallis
tests for more than two groups. All tests were conducted with an assigned significance level
of p<0.05.
Results
ECM1 is upregulated in aging and infarcted hearts, but not in pressure
overload cardiomyopathy
ECM1 mRNA (p = 0.0002) and protein (p = 0.0006) expression were significantly upregulated
in aging compared to young LV (Fig 1). Following-MI, a significant upregulation of ECM1
mRNA (p = 0.004) and protein (p = 0.005) occurred early in the ‘infarct zone’, relative to
healthy non-infarcted LV. The ‘border zone’ showed upregulation in ECM1 mRNA but not
protein (mRNA, p = 0.02; protein, p = 0.89) and no significant difference was seen in ECM1
expression in the ‘remote zone’. Later, at day 28, these changes are beginning to resolve. There
remained a slight numerical increase in ECM1 protein expression in the ‘infarct zone’, but this
was no longer significant. Following TAC, however, no significant difference in ECM1 mRNA
or protein expression was detected (S1 Fig). As ageing and MI are associated with inflamma-
tory cell infiltration into the left ventricle, we hypothesized that inflammatory cells may be
responsible for ECM1 expression.
Table 1. Flow cytometry antibody specifications.
Antibody Catalog # Clone Fluorophore Assay dilution Source
Rat Anti-Mouse I-A/I-E (MHC2) 563414 M5/114.15.2 BV711 1/1000 BD Biosciences
Rat Anti-CD11b 562287 M1/70 PE-CF594 1/750 BD Biosciences
Rat Anti-Mouse F4/80 565635 T45-2342 BV480 1/100 BD Biosciences
Rat Anti-Mouse CD117 563399 2B8 BV650 1/200 BD Biosciences
Hamster Anti-Mouse CD11c 560584 HL3 PerCP-Cy5.5 1/100 BD Biosciences
Rat Anti-Mouse CD3 564010 17A2 BV786 1/50 BD Biosciences
Rat Anti-Mouse Ly-6C 562727 AL-21 BV421 1/200 BD Biosciences
Rat Anti-Mouse CD45 552848 30-F11 PE-Cy7 1/1000 BD Biosciences
Rat Anti-Mouse Ly-6G 561105 1A8 FITC 1/100 BD Biosciences
Hamster Anti-Mouse FcεRI-α 134308 MAR-1 PE 1/400 Biolegend
https://doi.org/10.1371/journal.pone.0212230.t001
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ECM1 is expressed in BMCs and infiltrating cells in the infarct zone post-
MI
The cellular origin of ECM1 observed in LV samples remained unknown. We identified that
primary mouse CFbs do not express ECM1 protein under standard culture conditions, nor
when stimulated with recombinant TGF-β1 (10ng/ml) or ANG-II (100nM) (Fig 1). We inves-
tigated if ECM1 originated from other resident cardiac cells, or infiltrating inflammatory cells
in the heart. We cultured each of the known resident cell types in the heart separately to assess
ECM1 expression: primary human CFbs (1˚CFb), and human CFb cell line, human cardiac
myocytes (HCM), human coronary artery endothelial cells (HCAEC), human coronary artery
smooth muscle cells (HCASMC) and differentiated-HCASMC cell lines were cultured under
standard conditions and analyzed for ECM1 protein expression. No ECM1 protein was
detected from any cell type (Fig 2A). To investigate the possibility that ECM1 is of inflamma-
tory cell origin in the heart, bone marrow cells (BMCs) were then extracted from young
healthy mice. ECM1 protein was highly expressed in BMCs, and when separated into mono-
cyte and granulocyte cell fractions, there was significantly more ECM1 expression in the gran-
ulocyte fraction of BMCs (Fig 2A). ECM1 mRNA-FISH was then conducted on BMCs to
confirm mRNA expression (Fig 2B), followed by mRNA-FISH on frozen LV tissue sections
from day-3 post-MI animals to further investigate the cellular origin of ECM1 (Fig 2C). ECM1
mRNA was highly localized to the dense inflammatory cell infiltrate of the infarct and border
zones. Only minor expression of ECM1 was seen surrounding myocytes of the remote zone,
with no ECM1 expression seen within cardiac myocytes.
To further investigate the cellular source of ECM1+ cells, multicolour FISH-flow cytometry
was conducted on bone marrow cells, which had been tagged with an ECM1 mRNA-FISH
probe, alongside fluorescently labelled antibodies specific to the following cell surface markers:
Ly-6G, CD11c, Ly-6C, F4/80, CD117, MHC2, CD3, FcεrI-α, CD11b and CD45. Following
tSNE analysis, ECM1+ cells demonstrated expression (to varying levels) for CD45, CD11b,
CD11c, F4/80, Ly6-C, Ly-6G, and FcεrI-α, (Fig 3). Further, when visualising side scatter (SSC)
versus forward scatter (FSC) for ECM1+ cells, it is clear that ECM1+ cells are highly granular
and moderate to large in size, indicative of granulocytes (e.g. neutrophils, eosinophils) or large
cells such macrophages. Taken together, these results suggest that ECM1 is constitutively
expressed in granular bone marrow cells but not in smaller CD3+ or MHC II+ cells. Following
MI, ECM1+ cells may be recruited to the infarct zone of the LV to contribute to post-inflam-
matory fibrosis.
ECM1 stimulates collagen production from cardiac fibroblasts via
activation of ERK1/2 and AKT
Based on our findings of excess fibrosis and increased ECM1 expression in the aging and post-
MI LV, we explored whether ECM1 contributes to the observed fibrosis. Recombinant ECM1
was added to human CFb in culture and was sufficient to increase collagen production
(p = 0.004, Fig 4). To investigate the mechanism of collagen-I expression, we assessed several
Fig 1. ECM1 mRNA and protein levels are upregulated in aging LV tissue and in the infarct zone day-3 post-MI, but ECM1 is not
expressed by cardiac fibroblasts. ECM1 mRNA and protein (~75kDa) is upregulated in aging and specifically in the infarct zone of day-3
post-MI LV tissue. However, mouse primary cultured CFbs show no ECM1 expression under control conditions (Con.), nor in response to
48 h of treatment with recombinant TGF-β1 (10 ng/ml), or ANG-II (100nM) (left); positive control shows ECM1 expression in mouse LV
(LV—left lane). Data is expressed as mean ± SD. Control: n = 3 mice for mRNA, post-MI: n�6 mice/group for mRNA. Blot images of Day-3
post-MI, Day-28 post-MI and Mouse 1˚ CFb were cropped only to re-arrange the order of control lanes of the same blot. β-tubulin
(~55kDa) is included as the loading control. All protein n = 3 mice/group for each pathological state, and n = 3 technical replicates/group for
control Mouse 1˚ CFb, and n = 4 for TGF-β1 and ANG-II Mouse 1˚ CFb. �p<0.05; ��p<0.01; ���p<0.001 relative to control.
https://doi.org/10.1371/journal.pone.0212230.g001
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key signalling pathways involved in fibrosis (AKT, ERK1/2 & p38). Recombinant ECM1 signif-
icantly upregulated human CFb ERK1/2 activation (Thr202/Tyr204; p<0.0001) and AKT
Fig 2. ECM1 is not expressed by resident cardiac cells, but is highly expressed in bone marrow cells (BMCs) and cells in the infarct zone day-3 post-MI.
A) Immunoblot of ECM1 protein expression (~75kDa) in primary human CFbs, and cell lines: human CFb (CFb), human cardiac myocytes (HCM), human
coronary artery EC (EC), SMC (SMC) and SMC differentiated (SMC-D) cell lines (Left). No ECM1 protein expression is seen in any cell type; positive controls
show ECM1 expression in mouse LV (Ms-LV), and human atrial appendage (Hu-Atria), all data was normalized to β-tubulin expression as a loading control
(~55kDa). Immunoblot of ECM1 protein expression in BMCs from young healthy mice (middle, n = 3, HCM serve as a negative control), and in BMCs
separated into mononuclear and granulocyte fractions by Ficoll-Paque gradient density centrifugation (right, n = 4). A high level of ECM1 expression in BMCs,
with a significantly higher level of ECM1 expression in granulocytes (gran.), compared to monocytes (mono., p = 0.005); all data was normalized to β-Actin
expression as a loading control (~42kDa). B) mRNA-FISH of Ecm1 mRNA (white), conducted on BMCs in suspension; DAPI nuclear stain was used to
visualize cell nuclei (Blue). ECM1 mRNA is expressed in some BMCs (arrowhead), and not in other BMCs (full-arrow). C) mRNA-FISH of ECM1 mRNA
conducted on day-3 post-MI LV tissue, showing positive ECM1 expression as areas of sharp and punctate Cy5 fluorescent dots; example areas indicated by
arrowheads, DAPI nuclear stain was used to visualize cell nuclei (Blue). High ECM1 mRNA expression is seen in the infarct zone, some expression in the
border zone, and little expression in the remote zone, consistent with inflammatory cell infiltrate. In Fig 2A, positive controls and resident cardiac cells (right)
n = 1 technical replicates/group, BMCs n = 3/group, BMC monocytes and granulocytes n = 4/group. ��p<0.01 relative to control.
https://doi.org/10.1371/journal.pone.0212230.g002
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activation (Ser473) at 10 minutes (p<0.0001), and significantly downregulated AKT activation
at 50 minutes (p = 0.02) compared to untreated control human CFbs (Fig 4). No significant
difference in p38 activation (Thr180/Tyr182) was seen at any time-point.
Discussion
Here, we identified a novel association of ECM1 with cardiac aging and MI. ECM1 was upre-
gulated in the aging LV, and specifically in the infarct zone during the inflammatory phase
Fig 3. ECM1 FISH-Flow cytometry. ECM1 mRNA-FISH was coupled with flow cytometry to identify the cell surface
marker profile of ECM1 positive (ECM1+) cells in young healthy mouse bone marrow. A) Forward scatter area (FSC-A;
x-axis) versus side scatter area (SSC-A; y-axis) pseudocolour plot, demonstrating the gating strategy used to define our
“cells” population, in order to exclude debris; left graph. Forward scatter area (FSC-A; x-axis) versus forward scatter
height (FSC-H; y-axis) pseudocolour plot, demonstrating the gating strategy used to define “single cells” population, in
order to exclude cell doublets; middle graph. An image of mRNA-FISH of Ecm1 mRNA (white), conducted on BMCs in
suspension; DAPI nuclear stain was used to visualize cell nuclei (Blue); right image. B) FSC-A versus SSC-A
pseudocolour plot of the defined “single cells” population (left graph), and ECM1 (APC area channel) versus SSC-A
pseudocolour plot demonstrating the gating strategy used to define ECM1 positive (ECM1+) and ECM1 negative
(ECM1-) cells (middle graph). Included is FSC-A versus SSC-A of the ECM1+ gate overlayed onto the “single cells”
population. C) A pseudocolour plot of cell population clusters after tSNE analysis conducted on the concatenated
sample containing the gated populations from all four biological replicate samples combined (left graph; presented as
tSNE x-axis versus tSNE y-axis). All compensated channels were assessed: FITC (Ly-6G), PerCP-Cy5.5 (CD11c), BV421
(Ly6C), BV510 (F4/80), BV650 (CD117), BV711 (MHC2), BV786 (CD3), APC (ECM1), PE (FcεRI-α), PE-CF594
(CD11b), and PE-Cy7 (CD45). Gates corresponding to ECM1+ (blue) and ECM- (red) cells from the concatenated
sample was overlayed onto the tSNE pseudocolour graph (middle graph) to visualise expression levels of all cell surface
markers investigated, as represented by the corresponding histograms (right graph); x-axis corresponds to expression
level, y-axis corresponds to cells number.
https://doi.org/10.1371/journal.pone.0212230.g003
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early post-MI. Interestingly, there was no significant difference in ECM1 protein later post-
MI, suggesting a time-dependent expression profile of ECM1 post-MI. We showed that ECM1
was not expressed by any tissue resident cell type within the heart but was highly expressed in
BMCs, with a greater extent of ECM1 expression in granulocytes compared to monocytes.
ECM1 mRNA was visualized almost exclusively in inflammatory cells in the infarct zone and
infiltrating the border zone during the inflammatory phase day-3 post-MI. ECM1 is sufficient
for CFbs to produce collagen-I, supporting the hypothesis that ECM1 expression in the heart
Fig 4. ECM1 stimulates collagen-I expression and ERK1/2 and AKT pathway activation in cardiac fibroblasts. Collagen-I protein expression was
increased in human CFbs in response to 48 h of treatment with recombinant ECM1 (20ng/ml) relative to untreated control (Con.) cells (top left); data
normalized to β-tubulin expression (~55kDa). Immunoblots of ERK1/2 and p-ERK1/2 at Thr202/Tyr204 (top right), AKT and p-AKT at Ser473 (bottom
left), and p38 and p-p38 at Thr180/Tyr182 (bottom right) expression in human CFbs treated with recombinant ECM1 (20ng/ml) for 10, 30 or 50 minutes.
Shows significant ERK1/2 activation at 10, 30 and 50min, and AKT activation at 10min. Data is represented as phosphorylated/non-phosphorylated protein.
The blot image in top left figure was cropped only to re-arrange the order of control lanes of the same blot. All data is expressed as mean ± SD, with n = 3
technical replicates/group. �p<0.05, ��p<0.01, ����P<0.0001 relative to control.
https://doi.org/10.1371/journal.pone.0212230.g004
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originates from infiltrating inflammatory cells and contribute to cardiac fibrosis via activation
of ERK1/2 and/or Akt. A link between inflammation and fibrosis has long been appreciated,
but has mechanistically remained undefined. These findings propose a novel paradigm in
which ECM1, released from infiltrating inflammatory cells recruited from the bone marrow,
acts on fibroblasts resulting in collagen secretion.
Aging has been associated with cardiac fibrosis as the result of a multitude of factors includ-
ing cellular senescence, cell death and inflammation due to age-associated immunoinflamma-
tory dysregulation [12, 38–40]. Here we identified an increase in ECM1 expression in aging
mouse LV tissue. This is the first detection of ECM1 expression in the aging heart. Previous
studies have identified an inverse trend in the dermis where ECM1 expression decreases in
aging human skin [41, 42]. This opposing finding is likely due to the fact that the aging of
human skin is associated with decreased collagen and elastin content in the ECM leading to
fragmentation and disorganization of the remaining collagen fibres [42, 43]. In contrast, the
aging heart is associated with the accumulation of collagen, elastin and other ECM proteins
[38, 40], and a general shift in the expression of various matrix metalloproteinases (MMPs)
[44]. ECM1 has been identified to bind many ECM proteins, and is described as a multifunc-
tional binding core, and a biological glue [25, 33, 42, 45]. Thus, it is likely that ECM1 plays a
role in conferring structural stability to the cardiac ECM via its protein-protein binding capac-
ity, particularly in age-associated fibrotic ECM remodelling; similar to the previously proposed
role of ECM1 in the skin [42]. However, as ECM1 is expressed by TH1/2 lymphocytes, it is also
possible that the increase in ECM1 expression is a result of inflammatory cell infiltration to the
myocardium with aging [2, 35, 46].
We identified upregulation of ECM1 protein and mRNA at day-3 post-MI during the
inflammatory phase, selectively in the infarct zone. Day 1–3 post-MI is associated with acute
inflammation involving infiltration of lymphocytes, eosinophils, and neutrophils to the site of
infarct [20, 47–49]. One previous study has identified ECM1 expression in the heart during
chronic sustained hypoxia, with an associated increase in LV inflammation and ECM1 mRNA
expression [50]. This correlates with our results at day-3 post-MI and suggests that ECM1
plays a role in the post-MI inflammatory response. Although not focussed on cardiac disease,
another study identified ECM1 to be highly and selectively expressed by the TH2 subset of lym-
phocytes, and implicated ECM1 in controlling their egress from lymph nodes to the site of
inflammation in the respiratory system; ECM1 deletion resulted in significantly reduced aller-
gic airway inflammation in vivo, with reduced infiltration of eosinophils, macrophages and
lymphocytes [26]. Of particular interest is that ECM1 expression in TH2 lymphocytes occurred
only at day-3 post-antigen recognition and initiation of an immune response, the same time-
point of our identified ECM1 upregulation post-MI. This correlates with our findings and sug-
gests that ECM1 may play a similar role in the acute inflammatory response within 3 days
post-MI: facilitating the migration of TH2 lymphocytes, eosinophils and macrophages to the
site of infarct to promote the development of a fibrotic wound. This is plausible as TH2 lym-
phocytes (and other T lymphocytes) are crucial in promoting cardiac fibrosis through the
expression of growth factors, chemokines & cytokines and/or by direct cell-cell interaction
with fibroblasts to stimulate their activation, proliferation, trans-differentiation and matrix
generation [13, 51–54]. Our data suggests that the large granular cells from the bone marrow,
rather than lymphocytes, are responsible for ECM1 expression.
At 4–7 days post-MI during the transition into the proliferative phase, the inflammatory
response is halted and inflammatory cells are cleared from the infarct zone [20, 55]. The matu-
ration phase that follows at day-28 post-MI is associated with collagen crosslinking, ECM sta-
bilization, and fibroblast cell clearance from the site of infarct [20, 21, 55]. Herein we saw the
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increase in ECM1 expression was largely attenuated by day-28. Our findings suggest an early
inflammatory role of ECM1, rather than a structural role in post-MI fibrotic wound healing.
We showed that ECM1 is not detected in resident cardiac cells, but is highly expressed in
BMCs, with a significantly higher level of ECM1 expression in granulocytes compared to
monocytes. Further, multicolour FISH-Flow cytometry revealed ECM1+ bone marrow cells
are granular, and of medium to large size. We then identified for the first time that ECM1
+ cells are: Ly-6G-intermediate, CD11c-low, Ly-6C-intermediate, F4/80+, CD117-/low,
MHC2-, CD3-, FcεrI-α+, CD11b+ and CD45+. Based on our findings, it appears that ECM1
+ cells in the bone marrow of healthy, young mice are granulocytes or macrophages (e.g. neu-
trophils, eosinophils, mast cells) and likely not lymphocytes. No previous studies have been
conducted on ECM1+ cells in bone marrow of young healthy animals, however literature has
identified significant ECM1 expression in TH2 lymphocytes (at day-3 post antigen presenta-
tion). Although our findings are indicative of granulocytes, cells residing in the bone marrow
may have different expression of both ECM1, as well as cell surface markers, compared to cells
which have migrated to the infarct zone of the heart. Future studies will need to address the
identity of ECM1+ cells in the infarct zone post-MI, and should include functional cell mor-
phology data to provide a clear insight into the cellular origin of ECM1 in the heart.
Collectively, our results suggest that ECM1 expression in the heart is of inflammatory cell
origin, whether they be cardiac-resident inflammatory cells and/or infiltrating inflammatory
cells, and identifies a novel mechanism of multicellular signalling crosstalk via ECM1. This is
plausible as migration and phenotype shift of BMCs and other inflammatory cells to the site of
infarct during the inflammatory phase early post-MI is well established [56–59]. Further,
inflammatory cells including lymphocytes, monocytes, neutrophils, macrophages and eosino-
phils, have been identified to play pivotal roles in orchestrating ECM remodelling and fibrosis
in ischaemic wound healing in the infarct zone [47–49, 59]. Our in vitro findings correlate
with our observations of in vivo upregulation of ECM1 at day-3 post-MI during the inflamma-
tory phase, and considering other studies, suggest that ECM1 upregulation in the infarct zone
day-3 post-MI is due to infiltrating inflammatory cells.
We then demonstrated that recombinant ECM1 elicits a rapid activation of ERK1/2 and
AKT in CFbs, resulting in a downstream increase in collagen-I production. This is the first
report of ECM1 dependent CFb cell signalling, and demonstrates that ECM1 stimulates car-
diac fibroblast proliferative and pro-fibrotic pathways (AKT and ERK1/2, respectively), which
may contribute to fibrotic tissue formation with aging, and post-MI in vivo [60–64]. Future
studies are needed to elucidate: the specific inflammatory cell(s) of origin of ECM1, the mecha-
nism of migration of these cells to the myocardium, the mechanism of stimulating ECM1
expression, as well as the mechanism of ECM1 to CFb interaction and cell signalling to stimu-
late this novel fibrotic response.
Conclusion
Collectively, our findings suggest that ECM1 is expressed by infiltrating inflammatory cells,
not resident cardiac cells, and is sufficient for fibroblast stimulation and collagen production
in vitro. This suggests that ECM1 plays a role in cardiac fibrosis in aging and myocardial
infarction. ECM1 may be a novel intermediary between inflammation and fibrosis and a novel
therapeutic target.
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